KF
CADL icon

Krilogy Financial’s Candel Therapeutics CADL Stock Holding History

Krilogy Financial’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,065
Closed -$155K – 1084
2026
Q1 		$155K Buy
30,065
+6,065
+25% +$33K 0.01% 917
2025
Q4 		$144K Buy
+24,000
New +$129K ﹤0.01% 895

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Krilogy Financial's CADL Position: Q2 2026 in Review

Krilogy Financial sold out of Candel Therapeutics (CADL) in Q2 2026, closing a stake of 30,065 shares — an estimated $155K sold.

Krilogy Financial first reported a position in CADL in Q4 2025 and held it in 2 quarters. The position peaked at $155K in Q1 2026. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Krilogy Financial reported no remaining Candel Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Krilogy Financial sold 30,065 Candel Therapeutics shares in Q2 2026, an estimated $155K.
  • Krilogy Financial first reported a position in Candel Therapeutics in Q4 2025 and held it in 2 quarters.
  • Krilogy Financial's Candel Therapeutics position peaked at $155K in Q1 2026.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Krilogy Financial's 13F filing for Q2 2026, filed 27 Jul 2026.